A Study to Evaluate the Benefits and Risks of Conversion of Existing Adolescent Kidney Transplant Recipients Aged 12 to <18 Years to a Belatacept-based Immunosuppressive Regimen as Compared to Continuation of a Calcineurin Inhibitor-based Regimen, and Their Adherence to Immunosuppressive Medications
Clinical trial NCT04877288 · RECRUITING
Trial details
- NCT number
- NCT04877288
- Sponsor
- Bristol-Myers Squibb
- Status
- RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2021-07-21
- Primary completion
- 2032-12-30
- Enrollment
- 102
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.